Company Overview and News

47
How the Trump-China Trade Fight Is Rippling Through Corporate America - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AAI AA.PR FCX AA.PRB TCKRF AA TECK

24
The Curious Case Of Freeport-McMoRan

2018-06-11 seekingalpha
Freeport is entering the final stage of a multi-year restructuring strategy that will result in the company emerging with huge free cash flow, low debt, and numerous growth opportunities.
RTPPF RIO RIO RIO RTNTF FCX

8
Nevsun Resources Acquisition: The Bidders Try To Break The Institutional Investors

2018-06-09 seekingalpha
Euro Sun Mining amended its part of the offer to C$150 million in shares and C$150 million in cash.
NSU LUNMF CPNFD RVRLF FCX RMC LUNCF LUN

52
Freeport-McMoRan: Update On Bullish Thesis

2018-06-07 seekingalpha
In the beginning of May, I wrote an article "Freeport-McMoRan Will Rebound", outlining my bullish views after a sharp sell-off caused by new problems in Indonesia. Back then, I expected a rebound to the $17.00-20.00 range. The stock is now trading around $18, and several material developments have occurred, so it's high time to update.
RIO RIO BLT BHPBF FCX RTPPF BHP RIO BBL RTNTF BHP BHPLF

92
Euro Traders Set Themselves Up for a Letdown - Bloomberg

2018-06-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IFK C.WSA IFX C C.PRL C.PRJ C.PRK ALIZF FCX C.PRG C.PRC C.WS.B C.PRPCL CGBBW C.WS.A C.PRP C.PRU AZSEY C.PRS

9
FCX / Freeport-McMoRan Inc. 8-K (Current Report)

2018-06-05 sec.gov
Document UNITED STATES
FCX

8
Freeport-McMoRan: Strong Potential

2018-06-05 seekingalpha
Freeport-McMoRan has had a difficult few years, but the company is finally getting back on track.
FCX

22
Valuation Dashboard: Materials And Energy - Update

2018-06-05 seekingalpha
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages in each industry.
RRC RGRYY FCX MRO RRL RRS MLM RGRLF

8
FCX / Freeport-McMoRan Inc. DEFA14A

2018-06-01 sec.gov
Document UNITED STATES
FCX

383
7 Excellent Set-it-and-Forget-it ETFs for the Lazy Investor

2018-06-01 investorplace
To build long-term wealth for the big-ticket items and retirement, you need to invest. Keeping your money in a CD paying 2% won’t cut it. So, if you’re an investor seeking a set-it-and-forget-it exchange-traded fund (ETF) portfolio, then low-fee, diversified index funds are your solution.
PSA.PRA PSA.PRB IEX WDC MTB FCX ATO RDSB RDSA PSA.A LDOS AMZN VBR AAPL VOE PSAXZ TCTZF PSA.PRG RYDAF PSA.PRE PSA.PRF AVB PSA.PRC PSA.PRD VTR RDS.B STLD RDS.A TCEHY PSA.PRY PSA.PRZ CIG PSA.PRW PSA.PRX PSA.PRU CIGI PSA.PRV PSA PSA.PRS PSA.PRT SPG.PRJ JPM DPS RYDBF MSFT SPG

118
Cleveland-Cliffs: Too Cheap To Ignore Valuation Update

2018-05-31 seekingalpha
Cleveland-Cliffs (CLF) was the final stock profiled in my public Seeking Alpha "Too Cheap To Ignore" series in 2016. This series will make its return later this year, perhaps later in the summer, as there are a number of fundamentally cheap equities that have been overlooked amid the broader equity market froth of today, in my opinion. Before I start a new series of public Too Cheap To Ignore articles, I wanted to revisit the valuations of the entries in the previous series.
CKRGZ CHKVP FCX UNT CHKDH CHKVZ TECK CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI TWTR TCKRF CHK.PRD

17
FCX / Freeport-McMoRan Inc. SD

2018-05-29 sec.gov
Document UNITED STATES
FCX

25
Rio seen ready to sign $4.4b deal to exit giant Indonesian copper mine

2018-05-22 smh.com.au
Rio Tinto Group is ready to accept a $US3.5 billion ($4.4 billion) deal with Indonesia for its interest in the giant Grasberg copper and gold mine, according to people with knowledge of the discussions.
RTPPF RIO RIO RIO RTNTF FCX

24
Rio seen ready to sign $4.4b deal to exit giant Indonesian copper mine

2018-05-22 theage.com.au
Rio Tinto Group is ready to accept a $US3.5 billion ($4.4 billion) deal with Indonesia for its interest in the giant Grasberg copper and gold mine, according to people with knowledge of the discussions.
RTPPF RIO RIO RIO RTNTF FCX

214
Tracking Carl Icahn's Portfolio - Q1 2018 Update

2018-05-21 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
VLTCP CQP NAV.PRD CVI SDRPQ FCX PYPL TPCA AFSS AFST ENZN AFSI.PRC HRI AFSI.PRB AFSI.PRA NWL AFSI.PRF AFSI.PRE AFSI.PRD VLTCW WBT VKSC 8685 EBAY ARII AVF LNG GLPI KDUS AIG XRX IEP SD NAV CNDT SDOCQ HLF UAN AIG.WS ERI CVRR AFSI VLTC MTW SDRXP HTZ SDRXQ

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to FCX / Freeport-McMoRan Inc. on message board site Silicon Investor.

Freeport McMoran (FCX) McMoRan Exploration Co. (MMR)
Electric Fuel (efcx) Comments AFC Cable Systems (AFCX)
CUSIP: 35671D857